Aug 6, 2026 08:00AM
Aug 6, 2026 08:00AM
Jul 30, 2026 08:30AM
Jul 30, 2026 08:30AM
Jul 28, 2026 07:47AM
Jul 28, 2026 07:47AM
Jul 17, 2026 07:32AM FDA issues psychedelic therapy guidance as Clearmind notes federal push
Jul 17, 2026 07:32AM
Jul 10, 2026 08:32AM
Jul 10, 2026 08:32AM
Jun 22, 2026 08:07AM
Jun 22, 2026 08:07AM
Jun 16, 2026 07:32AM
Jun 16, 2026 07:32AM Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Jun 16, 2026 07:32AM
Jun 5, 2026 07:32AM
May 12, 2026 08:41AM
May 12, 2026 08:41AM
May 11, 2026 07:55AM
Apr 27, 2026 07:41AM
Apr 27, 2026 07:41AM Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Apr 20, 2026 04:03PM
Apr 20, 2026 04:03PM
Apr 20, 2026 07:15AM
Apr 20, 2026 07:15AM
Apr 15, 2026 07:31AM
Apr 15, 2026 07:30AM
Apr 14, 2026 07:32AM Clearmind Medicine's CMND-100 meets primary endpoint in phase trial
Apr 14, 2026 07:32AM
Mar 30, 2026 08:32AM
Mar 30, 2026 08:32AM
Mar 19, 2026 08:45AM
Mar 11, 2026 09:08AM
Mar 11, 2026 09:07AM
Mar 11, 2026 09:07AM Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
Mar 4, 2026 07:30AM
Mar 4, 2026 07:30AM
Mar 4, 2026 07:30AM
Feb 19, 2026 01:05PM
Feb 9, 2026 08:17AM
Feb 9, 2026 08:17AM
Feb 9, 2026 08:17AM Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
Feb 9, 2026 08:17AM
Jan 14, 2026 08:55AM
Jan 14, 2026 08:55AM
Dec 24, 2025 09:15AM
Dec 24, 2025 09:15AM
Dec 16, 2025 08:45AM
Dec 16, 2025 08:45AM Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Dec 1, 2025 08:57AM

327,802 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All